Dashboard

E-Commentary


Sponsored
joined 10 years, 4 months ago

Dr Richard Cooper

Registered Medical Practitioner

Qualified at Charing Cross Hospital in 1965 and was a Principal in NHS General Practice from 1966 until 1976. I am a registered medical practitioner and I have considerable experience in family medicine


view this profile
joined 10 years, 5 months ago

Elena Prousskaia

Consultant Plastic Surgeon

One of the very few female plastic and cosmetic surgeons in UK, Elena Prousskaia runs a modern cosmetic surgery practice in the South East of England and London. In addition to her exceptional credentials, Elena’s experience and friendly manner mean her skills are in huge demand.


view this profile
 

Prostate cancer develops in the walnut-sized gland underneath the male bladder. It is the most common cancer, other than skin cancer and is the second leading cause of cancer-related death in men.
 
The disease, which often develops slowly, is different to most other cancers because small areas of cancer within the prostate are common, especially in older men and may not grow or cause any problems. This presents men diagnosed with prostate cancer with some extremely difficult choices.
 
The statistics
Prostate cancer is the second most frequently diagnosed cancer in men and the fifth most common cancer overall. One in six men will be diagnosed with the disease in their lifetime and the overwhelming majority of cases occur in wealthy countries.
 
Each year, about 37,000 men in the UK and some 210,000 men in the US are diagnosed with prostate cancer and more than 10,000 and 28,000 respectively die each year of the disease. In the US there are over two million men living with the disease and African American men have a higher incidence of prostate cancer and double the mortality rate compared with other racial and ethnic groups. In the US about US$10 billion is spent annually on treatments for the disease. 
 
Standard treatments
Traditional treatments to stop the spread of prostate cancer involve surgery and radiotherapy, which has significant side effects. Following such treatments 50% of patients experience impotence, up to 20% suffer incontinence and between one and five percent who receive radiotherapy experience pain and bleeding.  
 
The standard PSA test is imperfect 
In the UK there is currently no national screening programme for prostate cancer. However, in 2002 the Prostate Cancer Risk Management Programme was introduced in response to a demand for the prostate specific antigen (PSA) test among men worried about prostate cancer. The Programme provides information to men about the benefits and risks of the PSA test, which is available, free of charge, to men over 50.
 
PSA is a protein produced by normal cells in the prostate and also by prostate cancer cells. All men have a small amount of PSA in their blood and elevated PSA suggests prostate problems, but not necessarily prostate cancer.
 
The test is imperfect and is not good at detecting prostate cancer early. In some cases, it completely misses cancers while in others it reports cancer when it is not present. This can lead to some difficult choices for men.
 
A 2013 study in Radiation Oncology supports earlier findings and suggests that men over 70 are better avoiding the PSA test since men with high risk prostate cancer are more likely to die of causes other than the disease.
 
The imperfections in PSA testing led, in 2011, to the US changing its guidelines on prostate cancer screening to suggest that healthy men should not take the test because of the risk of over diagnosing. Despite efforts to improve the PSA test, it is still recognised as the best non invasive prostate cancer test available.
 
Some good news for sufferers  
A promising new therapy to treat prostate cancer is high-intensity focused ultrasound (HIFU). HIFU therapy is a treatment modality of ultrasound involving minimally invasive or non-invasive methods to accurately destroy tumours by effectively heating them while doing far less damage to surrounding tissue and avoiding significant side effects. 
 
A 2012 clinical study reported in The Lancet suggests that HIFU therapy offers prostate cancer patients a significantly better treatment option than traditional methods and can be completed in a matter of hours during an outpatient visit to a hospital.
 
Clinical HIFU procedures are typically performed in conjunction with an imaging procedure to enable treatment planning and targeting before applying the therapeutic levels of ultrasound energy. MRI guided Focused Ultrasound Surgery (MRgFUS) combines a HIFU beam that non-invasively heats and destroys targeted tissue with MRI scanning that visualizes a patient’s anatomy and controls the treatment by continuously monitoring the tissue effect. 
 
Some other encouraging new therapies for prostate cancer
Recently, a new drug, enzalutamide (Xtandi), developed by the prestigious American prostate research centre in UCLA, has recently been licensed for use in the UK for patients with an advanced form of the disease and who have run out of treatment options.  
 
Also, there are some new FDA approved vaccines. One is sipuleucel-T (Provenge), which is designed to boost the body’s immune response to the prostate cancer cells. Another is PROSTVAC-VF, which uses a genetically modified virus containing PSA to trigger a response in a patient’s immune system to recognise and destroy cancer cells containing PSA.
 
Nutrition and Lifestyle
According to the World Health Organization, wealthy countries with the high meat and dairy consumption have the highest prostate cancer rates. This has encouraged scientists to examine foods and substances in them that may reduce the risk of prostate cancer.
 
Researchers suggest that lifestyle changes might affect the rate at which prostate cancer develops. One study reports that the level of PSA may be lowered by a vegan diet, regular exercise and yoga. Another suggests that a daily intake of flaxseed slows the rate at which prostate cancer cells multiply. Also, scientists suggest that lycopenes and isolflavones, found in tomatoes and soybeans respectively might help prevent prostate cancer.
 
Difficult choices for men
Given that patients decide about their treatment options and given that there are several treatment modalities for prostate cancer each with specific costs and risks; men diagnosed with prostate cancer face some difficult choices.
 
One challenge arises because genes linked to prostate cancer do not show which cancers are likely to remain within the prostate, which is normal for older men and which are more likely to grow and spread.
 
For example, researchers have found that the gene EZH2 is more frequent in advanced stages of prostate cancer, but this does not indicate how aggressive the cancer is. So, knowing of the genes presence does not help a patient make the important decision between immediate treatments or continued monitoring.
view in full page
 

  • Leading cancer scientist says we should abandon looking for a cancer cure
  • Another leading cancer scientist discovers key to killing all cancers
  • Cancer is an inevitable consequence of our multicellular make-up
  • Each person's cancer is unique
  • One in three people will develop cancer in their lifetime
  • Every day 1,500 Americans, and more non-Americans, die of cancer
Most cancers cannot be cured and scientists should devote their efforts to preventing and managing the disease instead of trying to find a cure. That’s the view of Melvyn Greaves Professor of Cell Biology at the Institute of Cancer Research, UK.

 

Game changing cure for all cancers

Greaves’ suggestion comes at a time when Professor Philip Ashton-Rickardt, from Imperial College London discovered a previously unknown protean, which boosts the body’s ability to fight off any cancer or virus. “This is a completely unknown protein. Nobody had ever seen it before or was even aware that it existed. It looks and acts like no other protein . . . . It could be a game-changer for treating a number of different cancers and viruses,” says Ashton-Rickardt.
 

Unanswered questions about cancer

Cancer is an uncontrolled cell proliferation, propelled by mutant genes that invade our tissues and hijack essential body functions.  Some regard this process as a ‘disease of the genome’. Around one in three of us will, at some time in our lives, be diagnosed with cancer; every day 1,500 Americans and vastly more non-Americans die of the disease. Missing from the narrative about cancer has been a coherent framework that makes sense of all its complexities and uncertainties: why are we so vulnerable to cancer, why is there so much diversity between different cancers, and even within single cancer types?  And why does treatment so often fail or only temporarily succeed?

Mike Birrer, Professor of Medicine, Harvard University Medical School and Director of Medical Oncology, Massachusetts General Hospital describes the Cancer Genome Atlas, a landmark cancer research program, which begins to address some of these questions: 


        

                                      

Previously undiscovered protein

The protein discovered by Ashton-Rickardt, named lymphocyte expansion molecule, or LEM, promotes the spread of cancer killing T cells by generating large amounts of energy. Normally when the immune system detects cancer it goes into overdrive trying to fight the disease, flooding the body with T cells. But it quickly runs out of steam.

The new protein discovered by Ashton-Rickardt causes a massive energy boost, which generates T cells in such great numbers that the cancer cannot fight them off. It also causes a boost of immune memory cells, which are able to recognise tumors and viruses they have encountered previously so there is less chance that they will return. Ashton-Rickardt, whose studies to-date have been in mice, is hoping to produce a gene therapy whereby T cells of cancer patients could be enhanced with the protein, and then injected back into the body. In three years he expects to begin human studies. If successful, Ashton-Rickardt’s discovery could end the need for chemotherapies, as the body itself would fight the disease, rather than toxic drugs.

Alex Walther, consultant medical oncologist and Director of Research in Oncology at University Hospitals, Bristol describes the challenges of clinical trails in personalised molecular medicine: 

        
                                                 

Need for smarter cancer strategies

Although sceptical about a cancer cure, Greaves has spent years unravelling the causes of childhood leukaemia by examining the genetic influences and biological pathways that lead to the disease. In 2008, breakthrough research led by Greaves and Professor Tariq Enver, achieved a world-first by confirming the existence of stem cells responsible for childhood acute lymphoblastic leukaemia.

Greaves insists that, “We need to get smarter. Very intelligent people who aren't scientifically minded think there must be a cause, there must be a cure, and it’s just not right. It’s fundamentally wrong . . . Talking about a cure for cancer in terms of elimination is just not realistic. . . . There are a few cancers that are curable, but most are probably not, including the common carcinomas in adults . . . . We should therefore not try to eliminate the cancer, we should try to hold it in check,” says Greaves. 
 

Experts disagree

Leading cancer expert Professor Karol Sikora, is confident cancer cures could still be found, and finds Greaves’ pessimism, “Strange, given that Professor Greaves has done so much to help find a cure for leukaemia. I absolutely think we will find new cures in the future, and the closer we get to understanding the mechanism of the disease, the quicker this will happen.

Professor Peter Johnson, chief clinician at Cancer Research UK agrees with Sikora, “We already have cures for many types of cancer. For example, millions of people who have had breast cancer, prostate cancer or bowel cancer are alive years after their surgery to remove the tumour, if it was caught early enough.” 
 

Molecular Darwinism 

Cancer researchers throughout the world are attempting to find cures for individual cancers using increasingly advanced methods. These include ramping up the body's own immune system to fight the disease; personalized treatments based on the DNA of the tumors, and gene therapies. But Greaves believes no therapy will work in the long term because tumors continue to evolve like all life forms. "Isn't it odd that when you read reports about new cancer therapies they work dramatically, but three months later, cancer is back with a bang. It's almost always the story" says Greaves. 

In his book, Cancer: The Evolutionary Legacy, Greaves describes the Darwinian process by which cancer cells mutate, and diversify by natural selection within our tissue ecosystems. According to Greaves cancer is an inevitable consequence of our make-up as a multicellular reproductive animal. Since multicellular organisms have been around for 700 million years there has been a long time for cancer to evolve; and, without DNA mutation, we ourselves would not have evolved, and adapted into what we are. According to Greaves, "Cancer becomes a statistical inevitability of nature; a matter of chance and necessity." 
 

Takeaways

Evolutionary principles derived from ecology, and the study of human evolution can change the way we think about the big question in cancer research. Will this provide new avenues for more effective cancer control or a cure? 

 
view in full page
 
 

Online video education can reduce the burden of diabetes

  • UK treatment costs for diabetes are £10bn per year and rising fast
  • London CCG adopts video education to reduce the burden of diabetes
  • Diabetes educational videos delivered directly to patients’ mobiles
  • Enhances patient satisfaction yet reduces face-time with doctors
  • Videos are peoples’ preferred way to receive healthcare information
  • Videos increase knowledge and self-management, and slows complications
  • Videos deliver 10 times the response rate of text and graphics

      


Managing My Diabetes is a new, evidence-based service, which offers a smarter and better way to engage and educate people with type-2 diabetes. It’s delivered by video directly to patients’ mobiles, and aims to significantly dent the eye watering, and rapidly escalating personal, financial and societal costs of this preventable condition. A London CCG is an early adopter. 

Dr Seth Rankin, co-chair of Wandsworth CCG’s Diabetes Group, Managing Partner of Wandsworth Medical Centre, and a long time advocate of the use of video in diabetes education, says, “In traditional doctor-patient consultations, patients often don’t absorb important information, and videos help to redress this. Managing My Diabetes engages patients, and provides them with trusted and convenient video information about their condition, which is a necessary prerequisite for any behavioural change”.

In addition to being the preferred format for patients to receive healthcare information, videos generate responses that are 10-times greater than that generated by text and graphics. Further, unlike health professionals, videos never wear out, they can be dubbed in any language, they’re easily and cheaply updated.
 

Importance of a patient user-base

Once people with diabetes are familiar with the initial Managing My Diabetes service, health providers can easily bolt on additional services to help people further manage their diabetes. This follows the model of digital champions such as Google and Facebook, which succeeded by using a simple core service, which successfully built a user base, and then, and only then, offered more services, thus continuously increasing the familiarity of their users with their services; and in turn the intensity with which they use them. Recently, the Department of Health failed to establish an online doctor-patient user-base for a £31m telehealth project, and it failed, see, Lessons from an axed telehealth project

Rankin describes the genesis and benefits of Managing My Diabetes:

      

        (click on the image to play the video) 


Video content library

Currently, there is no easy way for people with diabetes to quickly and easily obtain reliable online answers to their FAQs in video formats that they prefer, and there is no easy method for health professionals to post answers to patients’ questions about diabetes in a convenient online video format. 

At the heart of Managing My Diabetes is a content library of some 250 videos contributed by local health professionals, which address patients’ FAQs about managing their diabetes. Each video is between 60 and 80 seconds in duration, which is the average attention span of people seeking online video healthcare information. All videos are linked to bios of the contributors, which help patients judge the validity of the videos. 

Health professionals can cluster and send videos directly to patients’ mobiles to quickly and efficiently address their questions. Also, patients can rapidly access the entire diabetes video content library at any time, from anywhere on any devise. 

Managing My Diabetes is designed to: (i) enhance the connectivity between local health professionals and patients, (ii) increase the knowledge of diabetes among people with the condition, (iii) encourage self-management, (iv) slow the onset of complications, and (v) reduce face-time with doctors. 

Roni Saha, a consultant in acute medicine, diabetes and endocrinology at St George’s University Hospital, London, who contributed a portfolio of educational videos to Managing My Diabetes, describes risks for pregnant women with diabetes: 

       

     (click on the image to play the video) 
 

Traditional diabetes education has failed 

No one knows the true costs of type-2 diabetes, but its treatment costs alone are estimated to be some £10bn per year, and, in 20 years, expected to increase to £17bn; with diabetes complications costing a further £12bn per year. This highlights the pressing need to reduce the burden of the condition, which can be achieved by effective education. 

Traditional diabetes education that cost millions has failed to reduce the burden of diabetes. According to the National Diabetes Audit, less that 2% of people with diabetes attend any form of structured education. Instead, they regularly search the Internet for healthcare information, and use social media to share information they find. This is carried out at lightning speed, 24-7, 365 days a year. 

Health providers must come to terms with the fact that the balance of power has shifted from traditional providers of diabetes education to people living with the condition who are primarily interested in how education affects their outcomes. Failure to provide this link, leads to people disengaging and losing interest. 
 

What do people with diabetes want? 

Understanding the myths and realities about what patients really want from diabetes education is vital to capturing its value. A 2014 study by HealthPad into the efficacy of using videos in diabetes education concluded that there is a significant unmet need for trusted and convenient video educational material to help people manage their diabetes remotely: see: How GPs can improve diabetes outcomes and reduce costs. 
 

Age factor 

Because 63% of people with type-2 diabetes in England are over 60, a question that must be asked is whether delivering educational videos directly to their mobiles is really appropriate. The HealthPad study suggests that it is, and a 2014 McKinsey & Co survey on patients’ opinions of digital healthcare services agrees. Patients over 50 want digital healthcare services as much as younger counterparts. By 2018 smartphone penetration in the UK is expected to be almost 100%. The over 55s are experiencing the fastest year-on-year smartphone penetration, and the difference in smartphone penetration by age is expected to disappear by 2020, and Internet use has shifted from being exceptional to being commonplace.

Mobile devices are ubiquitous and personal, and competition will continue to drive lower pricing and increase functionality. Managing My Diabetes ensures that people living with diabetes will always be part of the doctor-patient network, which increases the variety; velocity, volume and value of educational information patients can receive.
 

Takeaways

Managing My Diabetes has been developed, tested and adopted by a London CCG. It has also a number of clinical champions. The service is designed to be easily and cost effectively embedded in primary care practices, and can be delivered in any language. 

If Managing My Diabetes is to dent the devastating burden of type-2 diabetes it will require national leadership to encourage CCG’s to adopt it, and health professionals to embrace it. Will NHS England and Diabetes UK play this much needed leadership role? If, in five years time, the burden of type-2 diabetes in England has not been significantly reduced, who will be accountable?

 
view in full page
 
In January 2015, a joint American-Australian research team won an American Epilepsy Society’s completion to detect seizures. The researchers developed an algorithm, which accurately predicts seizures 82% of the time. Previously, some health professionals believed that seizures could not be detected. “Until recently,” says Dr Francis Collins of the National Institute of Health, USA, “the best algorithm was hardly better than flipping a coin”.
 
Epilepsy
Epilepsy, which usually presents at the end of the first or second decade, is a chronic condition consisting of more than 40 clinical syndromes affecting about 50 million people worldwide. Its cause is unknown, but may stem from birth trauma, perinatal infection, anoxia, infectious diseases, ingestion of toxins, brain tumors, inherited disorders or degenerative disease, head injury, metabolic disorders, cerebrovascular accident, and alcohol withdrawal. Treatment is through medication or surgery, and the prognosis is variable.
 
The most common form of the condition is temporal lobe epilepsy (TLE), which is characterized by recurrent, unprovoked seizures. About 13% of patients receiving medication for TLE have inadequate seizure control. The prognosis for such patients includes a higher risk of memory loss, mood challenges, quality of life impairment, and, in some cases, death. 
Pharmacological management
Because the natural history of epilepsy varies between individuals and syndromes, it’s difficult to plot its course, and predict prognosis. Pharmacological management is complex, tailored to individual patients, and has variable efficacy. One of the most challenging pharmacological questions is when to begin medication. Overall, antiepileptic drug management is effective in controlling seizures in around 60-70% of individuals, and this is often achieved through a prolonged course of trial and error pharmacy.  
 
Surgical management
There are two categories of epilepsy surgery: one with curative intent, and another palliative. Selection criteria for surgery vary, but patients are generally considered when:
  • Their seizures are associated with a lesion amenable to surgery
  •  Supportive electrophysiological data
  • They’re resistant to medical therapy
  • No contraindications to surgery.
The aim of epilepsy surgery is a complete removal of the epileptogenic focus without further neurological damage. About 75% of epilepsy surgeries are localized neocortical resections for mesial temporal scleroses. Traditional outcome measures include seizure frequency and mortality. More recently, morbidity, and quality of life have become important outcomes. 
 
A new novel compound
Scientists from Louisiana State University, USA, have discovered a novel compound that curtails temporal lobe epilepsy, which  was thought to respond only to surgery.  A study published in 2015 in PLOS ONE, describes the affects of administering Neuroprotectin D-1, or NPD1, as a means of regulating the anomalous electrical activity in the brain.
 
Researchers discovered that the compound, derived from omega 3, and administered in mice, effectively reduces both micro seizures, which frequently occur before an epileptic episode, and the spontaneous recurrent seizures. Dr Nicolas Bazan, co-author of the study, said,  “These observations contribute to our ability to predict epileptic events, define key modulations of the brain circuits, and epileptogenisis“.  
view in full page
joined 10 years, 9 months ago

Daniel Glass

Consultant Dermatologist

Dr. Daniel Glass is an expert dermatologist, specialising in the diagnosis and treatment of a variety of skin conditions including eczema, acne skin cancer, psoriasis and rashes.


view this profile